- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01613690
Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment
December 16, 2020 updated by: Novartis Pharmaceuticals
An Open Label, Non-randomized, Parallel-group Study to Characterize and Compare the Pharmacokinetics, Safety, and Tolerability of a Single Dose of NVA237 in Subjects With Mild, Moderate, Severe and End-stage Renal Impairment With That in Matched Healthy Control Subjects
The purpose of this study is to see how the body processes and gets rid of NVA237 in people who have impaired kidney function compared to people whose kidney function is normal.
Study Overview
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Moscow, Russian Federation
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects age 18 to 70 years of age inclusive.
- Female subjects of childbearing potential must be using two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study, through study completion.
- Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 17 to 35 kg/m2.
- Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent
- For renal insufficient subjects only - Subjects must have stable renal disease without evidence of renal progressive disease (for the purpose of this study stable renal disease will be defined as no significant change for 12 weeks).
- For health subjects only - A serum creatinine within the normal range and an eGFR >80 mL/min/1.73 m2.
- For health subjects only - Matched to at least one renal impaired subjects undergoing study by age (±5 years), sex and weight (±10% BMI).
Exclusion Criteria:
- Smokers (use of tobacco products in the previous 3 months). Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine ≥ 500 ng/mL. If non-smoking subject are too difficult to recruit, smokers may be allowed to participate in the study provided they commit to smoke no more than 10 cigarettes/day during the days of PK-assessment
- For healthy subjects, use of any prescription drugs, herbal and fitness/bodybuilding/athletic performance-enhancing supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing
- Recent (within the last three [3] years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting (unless related to water withdrawal during dialysis), palpitations, etc).
- Recent (within the last three [3] years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
- History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study.
- Total WBC count which falls outside the range of 3000-12,000/μL, or platelets <100,000/μl at screening.
- History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy volunteers
control group receiving 100 μg NVA237
|
NVA237 is administered via a BREEZHALER device
|
Experimental: Mild renal impairment
(eGFR 50-80 mL/min/1.73m2)
receiving 100 μg NVA237
|
NVA237 is administered via a BREEZHALER device
|
Experimental: Moderate renal impairment
(eGFR 30-49 mL/min/1.73m2)
receiving 100 μg NVA237
|
NVA237 is administered via a BREEZHALER device
|
Experimental: Severe renal impairment
(eGFR <30 mL/min1.73m2)
receiving 100 μg NVA237
|
NVA237 is administered via a BREEZHALER device
|
Experimental: End-stage subjects requiring dialysis (ESRD)
receiving 100 μg NVA237
|
NVA237 is administered via a BREEZHALER device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of NVA2105 using PK parameter of primary interest - area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)
Time Frame: Day 1, 2, 3, 4 and 5
|
Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Concentration of NVA2105 using PK parameter of primary interest - maximum plasma concentration (Cmax)
Time Frame: Day 1, 2, 3, 4 and 5
|
Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Concentration of NVA2105 using PK parameter of primary interest - renal clearance (CLR)
Time Frame: Day 1, 2, 3, 4 and 5
|
Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Concentration of NVA2105 using PK parameter of secondary interest - time to Cmax (Tmax)
Time Frame: Day 1, 2, 3, 4 and 5
|
Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Concentration of NVA2105 using PK parameter of secondary interest - AUC extrapolated to infinity (AUCinf)
Time Frame: Day 1, 2, 3, 4 and 5
|
Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Concentration of NVA2105 using PK parameter of secondary interest - terminal elimination half-life, determined from plasma concentrations and urinary excretion rates (T1/2)
Time Frame: Day 1, 2, 3, 4 and 5
|
Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Concentration of NVA2105 using PK parameter of secondary interest - apparent systemic clearance (CL/F)
Time Frame: Day 1, 2, 3, 4 and 5
|
Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Concentration of NVA2105 using PK parameter - amount excreted into the urine from time 0 to 96 h post-dose (Ae0-96h)
Time Frame: Day 1, 2, 3, 4 and 5
|
Samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Urine, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Concentration of NVA2105 using PK parameter - T1/2
Time Frame: Day 1, 2, 3, 4 and 5
|
Samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Urine, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Concentration of NVA2105 using PK parameter - CLR
Time Frame: Day 1, 2, 3, 4 and 5
|
Samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Urine, Analyte: NVA237
|
Day 1, 2, 3, 4 and 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in effect of dialysis in End-stage subjects requiring dialysis (ESRD) using PK parameter Cmax
Time Frame: Day 1 of each treatment period
|
Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
|
Day 1 of each treatment period
|
Change in effect of dialysis in End-stage subjects requiring dialysis using PK parameter AUClast
Time Frame: Day 1 of each treatment period
|
Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
|
Day 1 of each treatment period
|
Safety and tolerability of a single inhalation dose of 100μg NVA237 in subjects with mild, moderate, severe, and end-stage renal impairment
Time Frame: Reviewed during each study visit
|
Adverse events will be based on evaluation of physical signs, electrocardiograms and clinical laboratory assessments
|
Reviewed during each study visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
November 1, 2010
Study Completion (Actual)
November 1, 2010
Study Registration Dates
First Submitted
June 5, 2012
First Submitted That Met QC Criteria
June 5, 2012
First Posted (Estimate)
June 7, 2012
Study Record Updates
Last Update Posted (Actual)
December 19, 2020
Last Update Submitted That Met QC Criteria
December 16, 2020
Last Verified
June 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CNVA237A2105
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Impairment
-
Eisai Inc.CompletedHepatic Impairment; Renal ImpairmentUnited States
-
JW PharmaceuticalCompletedHealthy, Renal ImpairmentKorea, Republic of
-
Kowa Research Institute, Inc.CompletedSevere Renal ImpairmentUnited States
-
Gilead SciencesTerminatedSevere Renal ImpairmentUnited States
-
Centre for Probe Development and CommercializationSt. Joseph's Healthcare Hamilton; McMaster UniversityCompleted
-
Sichuan Haisco Pharmaceutical Group Co., LtdThe First Affiliated Hospital of Zhengzhou UniversityCompletedChronic Renal ImpairmentChina
-
Novartis PharmaceuticalsCompletedMild and Moderate Renal ImpairmentRussian Federation, Germany, Serbia
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy Subjects | Severe Renal ImpairmentCzechia
-
Melbourne HealthWithdrawnRenal Impairment After Cardiac SurgeryAustralia
-
AstraZenecaCompletedRenal Impairment | Hepatic ImpairmentBulgaria
Clinical Trials on NVA237
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseUnited States, Germany, Hungary, Belgium, Poland, Spain, Netherlands
-
NovartisCompletedChronic Obstructive Pulmonary Disease (COPD)United States, Spain, Turkey, France, Netherlands, Germany
-
Novartis PharmaceuticalsWithdrawnChronic Obstructive Pulmonary Disease
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
-
NovartisCompletedChronic Obstructive Pulmonary Disease (COPD)Germany, Denmark
-
Novartis PharmaceuticalsWithdrawn
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)China, Philippines, Korea, Republic of, India
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseAustralia, New Zealand
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseUnited States